ASCO: Antibody Boosts Chemo in CLL – MedPage Today
ASCO: Antibody Boosts Chemo in CLLMedPage TodayCHICAGO — Adding the novel anti-CD20 agent obinutuzumab to standard chemotherapy for older, sicker patients with chronic lymphocytic leukemia improves outcomes, possibly more so than adding rituximab (Rit…
